Robenacoxib (BioDeep_00000182996)

 

Secondary id: BioDeep_00000013621

human metabolite blood metabolite


代谢物信息卡片


2-{5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]phenyl}acetic acid

化学式: C16H13F4NO2 (327.0882366)
中文名称: 罗贝考昔
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC1=CC(=C(C=C1)NC2=C(C(=CC(=C2F)F)F)F)CC(=O)O
InChI: InChI=1S/C16H13F4NO2/c1-2-8-3-4-12(9(5-8)6-13(22)23)21-16-14(19)10(17)7-11(18)15(16)20/h3-5,7,21H,2,6H2,1H3,(H,22,23)

描述信息

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

同义名列表

5 个代谢物同义名

2-{5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]phenyl}acetic acid; {5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]phenyl}acetic acid; 2-[5-Ethyl-2-(2,3,5,6-tetrafluoroanilino)phenyl]acetate; Robenacoxibum; Robenacoxib



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Peter Lees, Pierre-Louis Toutain, Jonathan Elliott, Jerome M Giraudel, Ludovic Pelligand, Jonathan N King. Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal of veterinary pharmacology and therapeutics. 2022 Jul; 45(4):325-351. doi: 10.1111/jvp.13052. [PMID: 35460083]
  • Verónica Vieitez, Victor López-Rámis, Rafael Barrera, Ignacio A Gómez de Segura. Serum C-reactive protein and iron levels following gonadectomy are not modified by perioperative administration of robenacoxib to dogs. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 2022 Jan; 86(1):40-47. doi: . [PMID: 34975221]
  • Jonathan N King, Wolfgang Seewald, Sophie Forster, Gabriele Friton, Derek E Adrian, B Duncan X Lascelles. Clinical safety of robenacoxib in cats with chronic musculoskeletal disease. Journal of veterinary internal medicine. 2021 Sep; 35(5):2384-2394. doi: 10.1111/jvim.16148. [PMID: 34196973]
  • Juliette Raulic, Francis Beaudry, Guy Beauchamp, Marion Jalenques, Noémie Summa, Stéphane Lair, Wahiba Ait Youcef, Claire Vergneau-Grosset. PHARMACOKINETIC, PHARMACODYNAMIC, AND TOXICOLOGY STUDY OF ROBENACOXIB IN RAINBOW TROUT (ONCORHYNCHUS MYKISS). Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians. 2021 Jun; 52(2):529-537. doi: 10.1638/2020-0130. [PMID: 34130395]
  • Jonathan N King, Martin Jung. Determination of the route of excretion of robenacoxib (Onsior™) in cats and dogs: A pilot study. Journal of veterinary pharmacology and therapeutics. 2021 May; 44(3):411-416. doi: 10.1111/jvp.12973. [PMID: 33881783]
  • Norihiko Oyama, Tadashi Sano, Mizuki Yamamori, Jun Tamura, Mohammed Ahmed Umar, Yusuke Endo, Yusyun Ishikawa, Akifumi Itoh, Kenjirou Miyoshi, Kazuto Yamashita. Influence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs. The Journal of veterinary medical science. 2018 Sep; 80(9):1450-1455. doi: 10.1292/jvms.17-0356. [PMID: 30078791]
  • Céline E Toutain, Patrick Brossard, Stephen B King, Rainer Helbig. Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations. BMC veterinary research. 2018 Aug; 14(1):242. doi: 10.1186/s12917-018-1566-1. [PMID: 30119677]
  • A Panteri, A Kukk, C Desevaux, W Seewald, J N King. Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs. Journal of veterinary pharmacology and therapeutics. 2017 Jan; 40(1):44-56. doi: 10.1111/jvp.12325. [PMID: 27302598]
  • Jonathan N King, Stephen King, Steven C Budsberg, B Duncan X Lascelles, Stephen E Bienhoff, Linda M Roycroft, Elizabeth S Roberts. Clinical safety of robenacoxib in feline osteoarthritis: results of a randomized, blinded, placebo-controlled clinical trial. Journal of feline medicine and surgery. 2016 08; 18(8):632-42. doi: 10.1177/1098612x15590870. [PMID: 26058587]
  • Jonathan N King, Alessandro Panteri, Melanie Graille, Wolfgang Seewald, Gabriele Friton, Cyril Desevaux. Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats. BMC veterinary research. 2016 Jun; 12(1):124. doi: 10.1186/s12917-016-0734-4. [PMID: 27338786]
  • L Pelligand, N Suemanotham, J N King, W Seewald, H Syme, K Smith, P Lees, J Elliott. Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney. BMC veterinary research. 2015 Dec; 11(?):296. doi: 10.1186/s12917-015-0598-z. [PMID: 26634699]
  • M Szweda, J Szarek, M Lew, A Szarek-Bęska, D Gulda. Can liquorice extract and herbal solution prevent colonic mucosa damage caused by robenacoxib in dogs?. Polish journal of veterinary sciences. 2015; 18(4):793-8. doi: 10.1515/pjvs-2015-0103. [PMID: 26812822]
  • L Pelligand, J N King, V Hormazabal, P L Toutain, J Elliott, P Lees. Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. Journal of veterinary pharmacology and therapeutics. 2014 Aug; 37(4):354-66. doi: 10.1111/jvp.12107. [PMID: 24628410]
  • Magdalena Szweda, Józef Szarek, Krystyna Dublan, Tomasz Męcik-Kronenberg, Zdzisław Kiełbowicz, Marcin Bigoszewski. Effect of mucoprotective plant-derived therapies on damage to colonic mucosa caused by carprofen and robenacoxib administered to healthy dogs for 21 days. The veterinary quarterly. 2014; 34(4):185-93. doi: 10.1080/01652176.2014.968939. [PMID: 25330194]
  • M Fink, I Letellier, M Peyrou, J P Mochel, M Jung, J N King, P Gruet, J M Giraudel. Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis. Research in veterinary science. 2013 Oct; 95(2):580-7. doi: 10.1016/j.rvsc.2013.04.021. [PMID: 23726662]
  • Jonathan N King, Martin Jung, Max P Maurer, Vincent B Schmid, Wolfgang Seewald, Peter Lees. Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats. American journal of veterinary research. 2013 Mar; 74(3):465-72. doi: 10.2460/ajvr.74.3.465. [PMID: 23438125]
  • David Bennett, Peter David Eckersall, Mary Waterston, Veronica Marchetti, Alessandra Rota, Eilidh McCulloch, Silvia Sbrana. The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis. BMC veterinary research. 2013 Mar; 9(?):42. doi: 10.1186/1746-6148-9-42. [PMID: 23452411]
  • Stephen King, Elizabeth S Roberts, Linda M Roycroft, Jonathan N King. Evaluation of oral robenacoxib for the treatment of postoperative pain and inflammation in cats: results of a randomized clinical trial. ISRN veterinary science. 2012; 2012(?):794148. doi: 10.5402/2012/794148. [PMID: 23738129]
  • J N King, J P Arnaud, E I Goldenthal, P Gruet, M Jung, W Seewald, P Lees. Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2. Journal of veterinary pharmacology and therapeutics. 2011 Jun; 34(3):298-311. doi: 10.1111/j.1365-2885.2010.01209.x. [PMID: 21492194]
  • Jerome M Giraudel, Philippe Gruet, Debbie G Alexander, Wolfgang Seewald, Jonathan N King. Evaluation of orally administered robenacoxib versus ketoprofen for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats. American journal of veterinary research. 2010 Jul; 71(7):710-9. doi: 10.2460/ajvr.71.7.710. [PMID: 20594071]
  • J N King, C Rudaz, L Borer, M Jung, W Seewald, P Lees. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. Research in veterinary science. 2010 Jun; 88(3):497-506. doi: 10.1016/j.rvsc.2009.11.002. [PMID: 20004922]
  • M Jung, P Lees, W Seewald, J N King. Analytical determination and pharmacokinetics of robenacoxib in the dog. Journal of veterinary pharmacology and therapeutics. 2009 Feb; 32(1):41-8. doi: 10.1111/j.1365-2885.2008.01035.x. [PMID: 19161454]
  • J N King, J Dawson, R E Esser, R Fujimoto, E F Kimble, W Maniara, P J Marshall, L O'Byrne, E Quadros, P L Toutain, P Lees. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. Journal of veterinary pharmacology and therapeutics. 2009 Feb; 32(1):1-17. doi: 10.1111/j.1365-2885.2008.00962.x. [PMID: 19161451]